Study evaluates use of tirzepatide in overweight/obese adults with type 1 diabetes

New research published in peer-reviewed journal Diabetes Technology and Therapies (DTT) evaluated the use of tirzepatide in overweight/obese adults with type 1 diabetes.

Tirzepatide is approved for the management of type 2 diabetes. Improves blood sugar control, promotes weight loss, and improves cardiovascular disease outcomes.

Satish Garg, MD, PhD, of the University of Colorado Denver, and his co-authors studied a group of adults with type 1 diabetes who were prescribed tirzepatide (off-label) and a control group of adults with type 1 diabetes who did not use any weight. compared. Medicine for loss. Researchers reported significant reductions in body mass index (BMI) and body weight in the treatment group compared to the control group. HbA1c decreased within 3 months in the treatment group and was maintained throughout the 1-year follow-up. Insulin doses decreased in the treatment group at 3 months and continued throughout the study period.

“We concluded that tirzepatide promoted an average of 18.5% weight loss (>46 pounds) and improved glycemic control in T1D patients after 1 year,” the researchers said.

“In the United States and Western Europe, most people with diabetes, both type 1 diabetes (T1D) and T2D, are overweight or obese,” said Satish Garg, MD, and co-author of an accompanying editorial. New treatments for diabetes, which not only improve blood sugar control but also cause significant weight loss and are known to reverse cardiovascular disease and diabetic kidney disease, are currently leading to a decline in type 1 diabetes in the United States. is not approved for use. “The use of GLP analogs in T1D patients presents many challenges, but with close follow-up, both patients and healthcare professionals can expect significant weight loss, reduced insulin doses, and the range of continuous glucose monitoring. “You may realize many benefits, such as increased internal time and improved HbA1c levels,” say the authors. There are no known long-term side effects such as gastroparesis, gastroesophageal reflux disease, or cholelithiasis from the use of her GLP analogs in diabetic patients. The authors recommend appropriate randomized controlled trials, especially for patients with T1D.